Soleno Therapeutics (SLNO) Cash from Investing Activities (2013 - 2026)

Soleno Therapeutics (SLNO) has 13 years of Cash from Investing Activities data on file, last reported at $38.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $38.0 million, up 65.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$186.7 million (down 113.41% YoY), and the FY2025 annual result was -$201.8 million, up 10.59% from the prior year.
• Cash from Investing Activities advanced to $38.0 million in Q1 2026 per SLNO's latest filing, from -$125.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $38.0 million in Q1 2026 and troughed at -$125.4 million in Q4 2025.
• A 4-year average of -$38.9 million and a median of -$4.0 million in 2022 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 119.9% in 2025 and fell as far as 2363.44% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at -$6000.0 in 2022, then jumped by 107483.33% to $6.4 million in 2024, then slumped by 2045.68% to -$125.4 million in 2025, then soared by 130.3% to $38.0 million in 2026.
• Business Quant data shows SLNO's Cash from Investing Activities at $38.0 million in Q1 2026, -$125.4 million in Q4 2025, and -$91.4 million in Q3 2025.